MERUVAX II SUMMARY
MERUVAX * II (Rubella Virus Vaccine Live) is a live virus vaccine for vaccination against rubella (German measles).
MERUVAX II is indicated for vaccination against rubella in persons 12 months of age or older.
Published Studies Related to Meruvax II (Rubella Vaccine)
Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine
using new measles and rubella working seeds in healthy children in Taiwan and
Singapore: a phase II, randomized, double-blind trial. 
seed virus stock, in Taiwanese and Singaporean children (NCT00892775)... CONCLUSION: The immune responses elicited by the MMRV(new WS) vaccine were
Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. [2011.06.06]
Co-administration of meningococcal ACWY-tetanus toxoid conjugate vaccine (ACWY-TT) with MMRV vaccine was investigated in 1000 12-23-month old children randomized (3:3:1:1) to receive co-administered ACWY-TT+MMRV, or a single dose of ACWY-TT, MMRV or MenC-CRM(197)... This study has been registered at www.clinicaltrials.gov NCT00474266.
Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. [2011.05.17]
BACKGROUND: The MMRV combination vaccine, Priorix-Tetra, is currently licensed in several European countries using a two-dose schedule in infants aged >/=9 months, with a preferred 6-week to 3-month interval between doses. This study was undertaken to generate safety and immunogenicity data for two doses of MMRV vaccine administered according to dose schedules using the shortest permitted interval of 4 weeks versus a longer interval of 12 months, which would allow flexible adaptation to local immunization calendars... CONCLUSIONS: Two doses of MMRV vaccine administered in the second year of life elicited adequate immunogenicity and were well-tolerated whether administered with a dose interval of 4 weeks or 12 months. Copyright (c) 2011. Published by Elsevier Ltd.
Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age. [2011.03]
The coadministration of the combined meningococcal serogroup C conjugate (MCC)/Haemophilus influenzae type b (Hib) vaccine with pneumococcal conjugate vaccine (PCV7) and measles, mumps, and rubella (MMR) vaccine at 12 months of age was investigated to assess the safety and immunogenicity of this regimen compared with separate administration of the conjugate vaccines...
Intralesional immunotherapy of common warts: successful treatment with mumps, measles and rubella vaccine. [2010.10]
BACKGROUND: Despite numerous therapeutic modalities reported in the literature, treatment of common warts remains a continuing challenge and there is no universal consensus about optimal treatment. Recently, intralesional immunotherapy by different antigens has proved efficacy in the treatment of different types of warts. OBJECTIVE: To evaluate the efficacy and safety of intralesional mumps, measles and rubella (MMR) vaccine in the treatment of common warts... CONCLUSIONS: Intralesional immunotherapy by MMR vaccine is a promising effective and safe treatment modality for common warts, particularly the multiple ones. (c) 2010 The Authors. Journal of the European Academy of Dermatology and Venereology (c) 2010 European Academy of Dermatology and Venereology.
Clinical Trials Related to Meruvax II (Rubella Vaccine)
Coadministration of Measles-rubella and Rotavirus Vaccines [Completed]
The investigators aim to establish the non-inferiority of concomitant administration of
measles-rubella and rotavirus vaccines to measles-rubella vaccine given alone in terms of
measles seroconversion rates. The primary study hypothesis is the measles seroconversion
rate as defined by the percentage of children seroconverting to measles with a measles serum
antibody concentration of >=1: 120 at 8 weeks post vaccination after the concomitant
administration of measles-rubella and rotavirus vaccines is non-inferior to that obtained
when measles-rubella vaccine is given alone in children 9 months of age who have received a
primary rotavirus vaccine series with the first dose between 6 and 10 weeks and the second
at least 4 weeks later and are seronegative for measles antibody in the pre-vaccination
Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. [Recruiting]
It is a clinicaltrial Phase III , randomized, double - blind , 4-arm (390 each one):
This study will include 1560 children and will use 3 batches of vaccine produced by Bio -
Manguinhos with viral bulk of GSK combined measles , mumps and rubella applied in healthy
children 12-15 months of age, and 01 batch of MMR to reference( GSK ), applied in healthy
children aged 12-15 months old . The vaccine is administered as MMR 1st dose.
Two hypotheses are tested :
1. Consistency of production ( equivalence between batches )of 3 batches of vacines(TV1,
TV2 , TV3 Bio- Manguinhos). Noninferiority vaccine Bio TV (Fiocruz, Rio de Janeiro),
ie, the measles, mumps and rubella in Brazil is as immunogenic and safe as the measles,
mumps and rubella reference, already used in routine NIP (production
Bio-Manguinhos/FIOCRUZ with viral concentrate, bulk, GSK).
The MMR vaccine (Bio-TV) will have the same composition (vaccine strains) and the same
method of production of MMR (TV-GSK): Wistar RA27 / 3 rubella, Schwarz strain of
measles vaccine, and strain RIT 4385 - derived from the Jeryl Lynn strain of mumps
As 2nd dose, children receive the vaccine tetraviral measles-mumps-rubella-varicella,
aged 15-18 months, according to the guidance of the National Immunization Program.
2. Noninferiority vaccine Bio TV (Fiocruz, Rio de Janeiro):the measles, mumps and rubella
vaccine in Brazil is as immunogenic and safe as the measles, mumps and rubella
reference, already used in routine NIP (production Bio-Manguinhos/FIOCRUZ with viral
concentrate, bulk, GSK).
Returns for blood sampling will be scheduled for 51 days, ranging from 42 to 60 days after
dose of MMR vaccine dose and after tetraviral. We will colect the firt blood sample before
the first vaccination too.
It will describe the major adverse events observed after vaccination , comparing their
frequency in groups of MMR vaccine with the Brazilian reference vaccine .
Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older [Active, not recruiting]
The purpose of this study is to evaluate the immunogenicity and safety of GSK's trivalent
MMR (Priorix®), comparing it to Merck"s MMR vaccine (M-M-R®II), which is approved for use in
The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine [Enrolling by invitation]
Nowadays these are some vaccines being vaccinated simultaneously, and a doubt is aroused if
the safety and immunogenicity are same between inoculating several vaccines simultaneously
and inoculating individually. So we carry out this study.
The purpose of this study is to evaluate the difference of safety and immunogenicity on
vaccinating rotavirus vaccine simultaneously with measles-rubella vaccine(MR) or
measles-mumps-rubella vaccine(MMR) compared to vaccinating rotavirus vaccine, MR or MMR
Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months [Completed]
- The primary objective of the study was to determine if intranasally administered influenza
virus vaccine, CAIV-T), when administered concomitantly with a subcutaneously administered
combination live, attenuated mumps, measles, and rubella (MMR) virus vaccine to children
interferes with the immune responses.
Page last updated: 2014-11-30